Data for December were not yet available. Kisqali is undergoing “a very rapid launch” in early breast cancer, Novartis CEO Vas Narasimhan said during a media call Friday. As Narasimhan shared ...

These TSX stocks have a high dividend-growth rate. Moreover, these stocks will likely grow their dividends at a solid pace.

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

A highly people-centric show talking about issues which matter to the citizens of Bharat.